The Business Advisory Board is composed of leaders in the life-sciences and finance world with experience in the pharmaceutical, biotechnology, medical device, investment banking, venture capital and financial management industries. The BAB members assess grant and investment opportunities and provide advice and direction to support the commercialization of new therapies. The BAB members also work with the SAB and the Board in setting strategic direction to guide the organization and our programs.

• Stephen D. Collins, M.D., Ph.D.:  Co-Chair, Business Advisory Board
  President & CEO, NeuroTherapeutics Pharma, Inc.
• Garry E. Menzel, Ph.D.: Co-Chair, Business Advisory Board
  Executive Vice President Corporate Development and Finance, Regulus Therapeutics
  

  ---

• Karen L. Bergman
  Founder and Principal, BCC Partners
• Thomas A. Bologna
  President & Chief Executive Officer, Orchid Cellmark, Inc.
• Rich Denness
  Formerly V.P. & General Manager, CNS, UCB, Inc.
• Frank Fischer
  President & CEO, NeuroPace, Inc.
• Jeffrey D. Glidden
  Executive Vice President & Chief Financial Officer, Parametric Technology Corporation
• Warren Lammert
  Founder, Managing Partner Granite Point Capital
• Lisa Lindahl
  Chief Executive Instigator at EZL Enterprises and Co-Founder and Partner at Bellisse
• Heath Lukatch, Ph.D.
  Partner, Novo Ventures
• Kevin Malone
  President and Founder, Greenrock Research
• Daniel J. O'Connell
  Director, NeuroVentures Capital LLC
• Sherrie Perkins
  Senior Director New Business Development, Cyberonics, Inc.
• David A. Sadock
  President & CEO, Ethos Health Communications
• Aaron Sandoski
  Managing Director, Norwich Ventures
• Nancy Santilli, B.S.N., M.S.N.
  VP Commercial Strategy and Portfolio Planning, Endo Pharmaceuticals, Inc.
• Ned Scheetz
  Managing Director, Aphelion Capital, LLC
• Lauren Silverman, Ph.D. 
  Managing Director, Novartis Option Fund
• Matthew Simonian
  Director of Global Marketing, UCB
• Reese S. Terry, Jr.
  Founder, Cyberonics, Inc.
• Gregory T. Went, Ph.D.
  CEO & Chairman, NeuroMolecular Pharmaceuticals, Inc.
• Joyce A. Cramer (ex officio), Chief Executive Officer, Epilepsy Therapy Project and Associate Research Scientist, Yale University School of Medicine